Safety, Tolerance, Efficacy and Pharmacokinetics of JS005 Multiple Dosing

NCT05344248 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

183

Enrollment

OTHER

Sponsor class

Conditions

Moderate to Severe Psoriasis

Interventions

BIOLOGICAL: JS005 (recombinant humanized monoclonal antibody against IL-17A)
BIOLOGICAL: JS005 placebo

Sponsor

Shanghai Junshi Bioscience Co., Ltd.